연구성과로 돌아가기
2022 연구성과별 연구자 정보 (1325 / 2879)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Hemp-Derived Nanovesicles Protect Leaky Gut and Liver Injury in Dextran Sodium Sulfate-Induced Colitis | Cho, Young-Eun | Cho, YE | 11 | 교신저자 | Andong Natl Univ, Dept Food & Nutr, Andong 36729, South Korea | 0000-0001-9864-0265 | , Young Eun | mcbaek@knu.ac.kr;yecho@anu.ac.kr; | ||
| Hepatic Protective Effects of Jujuboside B through the Modulation of Inflammatory Pathways | Lee, In-Chul | Lee, IC | 1 | Seowon Univ, Dept Cosmet Sci & Technol, Cheongju 28674, South Korea | baejs@knu.ac.kr; | |||||
| Hepatic Protective Effects of Jujuboside B through the Modulation of Inflammatory Pathways | Bae, Jong-Sup | Bae, JS | 2 | 교신저자 | Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Daegu 41566, South Korea | AAU-9724-2020 | Bae, Jong-Sup | baejs@knu.ac.kr; | ||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Hong, Jung Yong | Hong, JY | 1 | Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | 0000-0003-1363-9332 | Hong, Jung Yong | yh.paik@skku.edu;hoylim@skku.edu; | |||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Cho, Hee Jin | Cho, HJ | 2 | Precis Med Res Inst, Innovat Therapeut Res Ctr, Samsung Med Ctr, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Cho, Hee Jin | Cho, HJ | 2 | Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Sa, Jason K. | Sa, JK | 3 | Korea Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea | 0000-0002-3251-5004 | Sa, Jason Kyungha | yh.paik@skku.edu;hoylim@skku.edu; | |||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Liu, Xiaoqiao | Liu, XQ | 4 | Merck & Co Inc, Kenilworth, NJ USA | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Ha, Sang Yun | Ha, SY | 5 | Sungkyunkwan Univ, Dept Pathol & Translat Genom, Samsung Med Ctr, Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Lee, Taehyang | Lee, T | 6 | Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Kim, Hajung | Kim, H | 7 | Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Kang, Wonseok | Kang, W | 8 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Sinn, Dong Hyun | Sinn, DH | 9 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | JAC-4247-2023 | Sinn, Dong | yh.paik@skku.edu;hoylim@skku.edu; | |||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Gwak, Geum-Youn | Gwak, GY | 10 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | F-4605-2014 | Gwak, Geum | yh.paik@skku.edu;hoylim@skku.edu; | |||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Choi, Moon Seok | Choi, MS | 11 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; |
페이지 이동: